Novavax

+$4.74 (+2.31%) Today

$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Novavax and other stocks, options, and ETFs commission-free!

About NVAX

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome.

CEO

Stanley C. Erck

Employees

791

Headquarters

Gaithersburg, Maryland

Founded

1987

NVAX Key Statistics

Market Cap

15.54B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

3.41M

High Today

$211.27

Low Today

$201.65

Open Price

$205.00

Volume

2.55M

52 Week High

$331.68

52 Week Low

$43.60

NVAX News

ReutersJun 11

UPDATE 1-Novavax says COVID-19 vaccine shows immune response against Beta virus variant

(Adds details on studies) June 11 (Reuters) - Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the hi

MarketWatchJun 11

Novavax Reports Favorable Preclinical and Clinical Data for Vaccine

By Josh Beckerman Novavax Inc. reported favorable preclinical and clinical data for Covid-19 vaccine candidate NVX-CoV2373, including against variants original

Analyst Ratings

83%

of 6 ratings

Buy

83.3%

Hold

16.7%

Sell

NVAX Earnings

-$3.60

-$1.82

-$0.05

$1.73

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Estimated

— per share

Actual

Expected Aug 9, After Hours